Editas Medicine, Inc. (EDIT)

10.79
0.63 6.20
NASDAQ
Prev Close 10.16
Open 10.17
Day Low/High 10.10 / 10.64
52 Wk Low/High 9.71 / 73.03
Volume 129.53K
Exchange NASDAQ
Shares Outstanding 68.64B
Market Cap 685.71M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Premarket Movers

Upside - +90% (FDA grants Regenerative Medicine Advanced Therapy designation to SkinTE) - +37% (earnings, guidance) - +23% (Emergent Fidelity Technologies discloses 7.6% stake; crypto stocks higher as token prices and Tether stabilize) - +20% (earni...

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen

Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.

Are You Investing -- Or Just Gambling?

Are You Investing -- Or Just Gambling?

Here's the difference between the two, using two biotech companies, Mannkind and Editas.

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

These ARK Funds family funds are focused on new opportunities and investment themes.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

Buy Opportunities Dry Up as Stock Market 'Gaps and Slips'

You have to be willing to chase if you want to establish new positions.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

Pacific Biosciences Shares Down After Third-Quarter Results -- Biotech Movers

The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers

Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.

Editas upgraded at Jefferies

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.